Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial

Targeted Oncology

Volumn 9, Issue 3, 2014, Pages 273-277

  Penel, Nicolas ^a,b   Ray Coquard, Isabelle ^c   Bal Mahieu, Christine ^a   Chevreau, Christine ^d   Le Cesne, Axel ^e   Italiano, Antoine ^f   Bompas, Emmanuelle ^g   Clisant, Stéphanie ^a   Baldeyrou, Brigitte ^a   Lansiaux, Amélie ^a   Robin, Yves Marie ^a   Bay, Jacques Olivier ^h   Piperno Neumann, Sophie ⁱ   Blay, Jean Yves ^c   Fournier, Charles ^a  

^a Oscar Lambret Centre   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CENTRE LÉON BÉRARD   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f INSTITUT BERGONIÉ   (France)

^g Institut de Cancerologie de l'Quest Rene Gauducheau   (France)

^h Surgical Department   (France)

ⁱ INSTITUT CURIE   (France)

Author keywords

Angiogenesis; Placenta growth factor; Sorafenib; Vascular sarcoma; VEGF

Indexed keywords

EID: 84887037183     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0299-0     Document Type: Article

References (23)

1. Penel N, Marreaud S, Robin YM, Hohenberger P (2011) Angiosarcoma: state of the art and perspectives. Crit Rev Oncol Hematol 80:257–263
2. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY (2008) Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol 26:5269–5274
3. Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Hallscheidt P, Schirmacher P, Weitz J, Friess H, Buchler MW, Schmidt J (2006) Primary malignant hepatic epithelioid hemangioendothelioma. Cancer 107:2108–2121
4. Kitaichi M, Nagai S, Nishimura K, Itoh H, Asamoto H, Izumi T, Dail DH (1998) Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. Eur Respir J 12:89–96
5. Flaherty KT (2007) Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 7:617–626
6. Adnane L, Trail PA, Taylor I, Wilhelm SM (2006) Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597–612
7. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109
8. Brown L, Tognazzi K, Dvorak HF, Harrist TJ (1996) Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi and cutaneous angiosarcoma. Am J Pathol 148:1065–1074
9. Naito S, Shimizu K, Nakashima M, Ito T, Ito M, Yamashita S, Sekine I (2000) Overexpression of Ets-1 transcription factor in angiosarcoma of the skin. Pathol Res Pract 196:103–109
10. Itakura E, Yamaoto H, Oda Y, Tsuneyoshi M (2008) Detection and characterization of vascular endothelia growth factors and their receptors in a series of angiosarcoma. J Surg Oncol 97:74–81
11. LaMontagne KR Jr, Moses MA, Wiederschain D, Mahajan S, Holden J, Ghazizadeh H, Frank DA, Arbiser JL (2000) Inhibition of MAP kinases causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol 157:1937–1945
12. Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, Qin LX, Brennan MF, Singer S, Maki RG (2009) KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibition. Cancer Res 69:71–79
13. Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD, Phung TL, Pollock RE, Benjamin R, Hunt KK, Lazar AJ, Lev D (2010) Angiosarcoma: clinical and molecular insights. Ann Surg 251:1098–1106
14. Emamaullee JA, Edgar R, Toso C, Thiesen A, Bain V, Bigam D, Kneteman N, Shapiro AM (2010) Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: implications for treatment and surgical management. Liver Transpl 16:191–197
15. Hatva E, Böhling T, Jääskeläinen J, Persico MG, Haltia M, Alitalo K (1996) Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 148:763–775
16. Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C, Bay JO, Bousquet G, Piperno-Neumann S, Isambert N, Lemaitre L, Fournier C, Gauthier E, Collard O, Cupissol D, Clisant S, Blay JY, Penel N, French Sarcoma Group (GSF/GETO) (2012) Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist 17:260–266
17. Chevreau C, Le Cesne A, Ray-Coquard I, Italiano A, Cioffi A, Isambert N, Robin YM, Fournier C, Clisant S, Chaigneau L, Bay JO, Bompas E, Gauthier E, Blay JY, Penel N (2013) Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the Fench Sarcoma Group (GSF/GETO). Cancer. doi:10.1002/cncr.28109
18. Tokuyama W, Mikami T, Masuzawa M, Okayasu I (2010) Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR63 signaling in angiosarcomas of the scalp and face. Hum Pathol 41:407–414
19. Lovet JM, Pena CE, Lathia CD, Shan M, Meinherdt G, Bruix J, SHARP Investigators Study Group (2012) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18:2290–2300
20. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 16:4853–4863
21. Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M et al (2012) Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One 7:e26331
22. Sleijfer S, Gorlia T, Lamers C, Burger H, Blay JY, Le Cesne A et al (2012) Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft tissue sarcoma: an EORTC-STBSG study. Eur J Cancer 107:639–645
23. Sleijfer S, Ouali M, Van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A et al (2010) Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 46:72–83